Q3 2025 Zymeworks Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: €15.3 (+1.32%)

Transcript 10-Q8-K

Key Points

Positve

Zymeworks Inc (ZYME) reported a significant increase in total revenue to $27.6 million for Q3 2025, up from $16 million in Q3 2024, primarily due to a $25 million milestone from J&J.
The company achieved a $25 million development milestone from its collaboration with J&J, highlighting the strength of its partnerships.
ZW 191 showed promising early clinical data with a favorable safety profile and meaningful reductions in tumor size across multiple dose levels.
Zymeworks Inc (ZYME) completed share repurchases of $22.7 million, reflecting confidence in the company's outlook and commitment to shareholder value.
The company remains well-capitalized with $299.4 million in cash equivalents and marketable securities, expected to fund operations into the second half of 2027.

Negative

Operating expenses remained high at $49.7 million for Q3 2025, only slightly reduced from $50.2 million in Q3 2024.
Net loss for Q3 2025 was $19.6 million, although improved from a $29.9 million loss in Q3 2024, indicating ongoing financial challenges.
Cash resources decreased to $299.4 million as of September 30, 2025, from $324.2 million at the end of 2024.
The company discontinued the development of ZW 171 due to it not meeting internal thresholds, reflecting challenges in its pipeline.
There is uncertainty regarding the timing and realization of future milestones and royalties, which could impact financial projections.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZYME.OQ - Zymeworks Inc
Q3 2025 Zymeworks Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by.

This is the conference operator. Welcome to the Design Works 3rd quarter 2025 results conference call and webcast. As a reminder, all participants are in a listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To ask a question, press 11 on your telephone keypad.

Should you need assistance during the conference call, you may signal an operator by pressing and then 0. I would now like to turn the conference over to Saranal Innamander, senior, excuse me, senior director of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.